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Chronic hepatic inflammation involves a complex interplay of inflammatory and mechani-
cal influences, ultimately manifesting in a characteristic histopathology of liver fibrosis. We
created an agent-based model (ABM) of liver tissue in order to computationally examine
the consequence of liver inflammation. Our liver fibrosis ABM (LFABM) is comprised of
literature-derived rules describing molecular and histopathological aspects of inflammation
and fibrosis in a section of chemically injured liver. Hepatocytes are modeled as agents
within hexagonal lobules. Injury triggers an inflammatory reaction, which leads to activa-
tion of local Kupffer cells and recruitment of monocytes from circulation. Portal fibroblasts
and hepatic stellate cells are activated locally by the products of inflammation. The vari-
ous agents in the simulation are regulated by above-threshold concentrations of pro- and
anti-inflammatory cytokines and damage-associated molecular pattern molecules.The sim-
ulation progresses from chronic inflammation to collagen deposition, exhibiting periportal
fibrosis followed by bridging fibrosis, and culminating in disruption of the regular lobu-
lar structure. The ABM exhibited key histopathological features observed in liver sections
from rats treated with carbon tetrachloride (CCl4). An in silico “tension test” for the hepatic
lobules predicted an overall increase in tissue stiffness, in line with clinical elastography liter-
ature and published studies in CCl4-treated rats.Therapy simulations suggested differential
anti-fibrotic effects of neutralizing tumor necrosis factor alpha vs. enhancing M2 Kupffer
cells. We conclude that a computational model of liver inflammation on a structural skele-
ton of physical forces can recapitulate key histopathological and macroscopic properties of
CCl4-injured liver.This multiscale approach linking molecular and chemomechanical stimuli
enables a model that could be used to gain translationally relevant insights into liver fibrosis.
Keywords: cirrhosis, computer simulation, inflammation, elastography, hepatocyte
INTRODUCTION
Fibrosis is an aberrant wound-healing response characterized
by excessive deposition of scar tissue composed of extracellu-
lar matrix (ECM) proteins. In the liver, fibrosis is caused by
chronic inflammation arising from viral hepatitis, alcohol, drugs,
and metabolic or autoimmune diseases (Friedman, 2008). Pro-
gressive fibrosis distorts liver vasculature and architecture, leading
to cirrhosis (Schuppan and Afdhal, 2008). Secondary effects of
liver cirrhosis result in approximately 35,000 deaths each year
Abbreviations: ABM, agent-based model; CCl4, carbon tetrachloride; DAMP,
damage-associated molecular pattern; ECM, extracellular matrix; HMGB1, high
mobility group box protein 1; HSC, hepatic stellate cell; LFABM, liver fibrosis agent-
based model; TGF-β1, transforming growth factor beta 1; TNF-α, tumor necrosis
factor alpha.
in the US (1.2% of all US deaths). As organ transplant is the
only available treatment for cirrhosis, a better understanding of
fibrosis is needed. Decades of research have elucidated many cel-
lular effectors and key cytokines regulating the fibrotic process,
the interplay of inflammation and repair, and determinants of
ECM turnover (Iredale, 2007). However, translation of this knowl-
edge into anti-fibrotic therapies remains a challenge, as fibrotic
pathology in humans can only be observed in diagnostic biopsies,
which are invasive, risky procedures, and are usually performed
on patients in advanced stages of disease (Popov and Schuppan,
2009).
Inflammation and fibrosis are closely linked. Injury elicits
recruitment of inflammatory cells to the liver, as well as acti-
vation of resident inflammatory cells, and a close topographical
relationship between the site of inflammation and development of
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fibrosis is seen in vivo (Sorensen et al., 1984; Tsukamoto et al., 1990;
Constandinou et al., 2005; Iredale, 2007). Liver inflammation acti-
vates hepatic stellate cells (HSCs) to a myofibroblastic phenotype,
the main source of hepatic collagens in fibrosis (Friedman, 2008).
Activated HSCs remodel the local ECM from its normal low den-
sity basement membrane-like consistency to one that is three-
to fivefold more dense, with high collagen content (Friedman,
2000; Schuppan et al., 2001). With progressing fibrosis, ECM stiff-
ness increases, thereby reducing liver elasticity (Wang et al., 2009).
There is growing interest in the role of ECM stiffness not only as
a consequence of fibrosis, but also as a contributor to fibrogenesis
(Georges et al., 2007; Wells, 2008). Diagnostic technologies of liver
stiffness, such as ultrasound or magnetic resonance elastography,
are emerging, non-invasive alternatives to biopsy (Castera et al.,
2005; Huwart et al., 2006; Takeda et al., 2006; Yin et al., 2007).
Despite in vitro evidence that matrix stiffness plays a deter-
minant role in the phenotype of most adherent cells, there is
little evidence that these findings apply in vivo. It is also unclear
how macro-level tissue changes affect individual cells, which
only mechanosense over short distances (Wells, 2008). Structural
changes in cirrhosis can be extensive before the onset of functional
hepatic decompensation; thus, it is also unclear how hepatocytic
or ECM changes may play a role in shifting parenchymal cell func-
tion toward organ failure. Our liver fibrosis ABM (LFABM) is an
in silico model that begins from simulation of healthy liver tissue,
and, in response to toxic injury, progresses to a fibrotic phenotype
characteristic of cirrhosis. In the LFABM, local cell mechanics and
fibrotic development lead to overall matrix stiffness in the liver
tissue.
Computational (in silico) modeling provides a means of
addressing such questions, where in vivo and in vitro models are
either inadequate or infeasible. In particular, translational sys-
tems biology aims to use computational methods to generate
and test hypotheses regarding dynamic, complex disease processes
(Vodovotz et al., 2008). One such method is the use of agent-
based models (ABMs) to integrate local interactions to recapitulate
overall dynamic changes in the referent biological system, thereby
facilitating the generation of mechanistic hypotheses regarding
emergent spatial or temporal patterns that often result in biologi-
cal systems (An et al., 2009). ABMs have been used to gain clinical
insights into several areas of clinical interest (An, 2004; Segovia-
Juarez et al., 2004; Mi et al., 2007; Li et al., 2008; Brown et al.,
2011). In the field of liver research, ABMs have been used to test
hypotheses regarding the mechanistic details of hepatic drug dis-
position (Park et al., 2009), specific pathways for dioxin-induced
toxicity (Bhattacharya et al., 2012), and dose–response across the
sinusoidal network (Wambaugh and Shah, 2010). All of these
model the liver from a pharmacological perspective. ABMs can
also be used to explore coordinated cell behavior, such as during
short-term liver regeneration (Hoehme et al., 2010). In our work,
we present an ABM that simulates the development of chronic
liver inflammation and fibrosis based on both molecular interac-
tions and mechanical forces, by employing a multiscale modeling
approach in which phenomenological rules are combined with
biomechanical rules (Vodovotz et al., 2008; Meier-Schellersheim
et al., 2009). Key predictions regarding emerging histological pat-
terns were validated against experimental data from CCl4-treated
rats (Grimm et al., 2005). In addition, two theoretical anti-fibrotic
therapies were compared in silico.
MATERIALS AND METHODS
AGENT-BASED MODEL
The LFABM consists of agents representing parenchymal cells
(hepatocytes, live and dead), inflammatory cells (Kupffer cells),
collagen-producing cells (HSCs and portal fibroblasts), and struc-
tural elements that define lobules (portal triads and septa). Agents
can produce diffusible factors [tumor necrosis factor alpha (TNF-
α), transforming growth factor beta 1 (TGF-β1), high mobility
group box protein 1 (HMGB1)] that are subject to degradation,
and can affect each other, or other agents. The properties of these
agents and their interactions with each another are governed by
rules obtained from the published literature. Details of these rules
are available in Supplementary Material and a brief overview
is provided in the Section “Modeling Cellular Interactions and
Inflammation.”
All agents occupy space, and have the ability to identify other
agents with which they come in contact. Agents representing hepa-
tocytes, dead hepatocytes, septa, portal triads, and collagen are
considered to contribute to tissue mechanics, and therefore pos-
sess the property of collision. Collision is defined in the context of
our LFABM as the ability of an agent to occupy its own space, and
exert force upon another agent when encountered. This property is
important for biological fidelity to tissue mechanics. Since Kupffer
cells, HSCs, portal fibroblasts, and myofibroblasts are not struc-
tural components of the organ tissue, these agents are assumed not
to contribute to tissue mechanics by their physical presence, and
therefore do not possess the property of collision. Consequently,
these agents can co-exist in the same space, and our model would
not capture any changes in size or elasticity due to physical pressure
from inflammatory infiltrates.
The LFABM was implemented using Simple Platform for
Agent-based Representation of Knowledge (SPARK) (Solovyev
et al., 2010). Source code for the model is available for download
at http://www.pitt.edu/~cirm/spark/models/LFABM.zip (Tutori-
als for SPARK and other ABM examples are freely available at
http://www.pitt.edu/~cirm/spark).
ANIMAL MODEL FOR ABM VALIDATION
In order to observe the histological pattern of fibrosis development
over time, we obtained slides from an animal model of experimen-
tally induced fibrosis. All procedures performed on animals were
approved by the University of Pittsburgh Animal Care and Use
Committees. Liver fibrosis was induced in male Lewis rats using
CCl4 as described previously (Kobayashi et al., 2000; Liu et al.,
2012).
Briefly, liver cirrhosis was induced beginning in 4-week-old
inbred male Lewis rats, weighing 100–130 g, using Phenobarbital
(Sigma Chem. Co., St. Louis, MO, USA) and carbon tetrachloride
(CCl4, Sigma) (Kobayashi et al., 2000). Rats were given Pheno-
barbital (0.5 g/l) added to the drinking water. Starting 2 weeks
later, CCl4 (diluted 1:9 in the olive oil) was administered by gav-
age on a full stomach twice a week. Following an initial dose
of 0.2 ml/kg, each subsequent dose was adjusted weekly on the
basis of changes in body weight. If the body weight increased
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or remained unchanged, CCl4 was continued at 0.2 ml/kg twice
weekly. When body weight decreased by 1–5 g, the dose of CCl4 was
reduced to 0.15 ml/kg, and if body weight decreased by 6–10 g the
CCl4 was reduced to 0.1 ml/kg. In rats that lost more than 10 g of
body weight, CCl4 was withheld until reassessment 1 week later. All
animals receiving CCl4 were observed for 4 weeks after receiving
their last dose of CCl4 to eliminate the acute effects of toxin expo-
sure before any analysis was performed. Animals receiving CCl4
over 26–28 weeks generated cirrhosis that produced irreversible
liver failure, and these animals died approximately 2–4 weeks after
the 4-week observation period with progressive worsening of liver
function. Animals with cirrhosis without liver failure received 13–
14 weeks of CCl4. Laboratory tests and ascites resolved quickly
in all of these animals after the 4 week observation period after
discontinuing CCl4.
Masson’s trichrome stain was applied to distinguish collagen
deposits.
MODELING THE LIVER LOBULES
A patch of liver tissue was modeled as a two-dimensional mono-
layer of 3,857 hepatocytes (see Model Calibration and Parameter
Estimation) arranged in lobules, as seen in Figure 1. Each septum,
forming an edge of a lobule, was modeled by two boundary agents
placed side by side, and connected with a prismatic joint. This
type of joint allows the entities to slide along each other, if free to
move. Each septum was connected to its adjacent portal triad by
a revolute joint, which allows rotation around the portal triad, if
free to move. Freedom of motion was determined by the relative
physical forces exerted by tissue components.
MODELING CELLULAR INTERACTIONS AND INFLAMMATION
Hepatocytes are known to be long-lived under normal, healthy
conditions, and have rapid regenerative capacity to replace hepato-
cytes lost due to resection or other means (Roskams, 2008). In the
LFABM, agents representing hepatocytes have long lifespans and
monitor their neighboring spaces. If empty space is detected, the
hepatocyte replicates to fill that space. If, however, excess collagen
is detected, the hepatocyte cannot replicate more than twice. This
rule was incorporated to simulate suspected replicative senescence
from observations in our previous work (Liu et al., 2012).
The sequence of events in the LFABM is shown in Figure 2.
Administration of CCl4 in animal models causes centrilobular
necrosis of hepatocytes (Stachura et al., 1981). In our model,
pulses of centrilobular toxicity transform hepatocytes into dead
agents. Biologically, Kupffer cells survey the area and phagocy-
tize dead cells and become activated to produce cytokines in the
process (Edwards et al., 1993). In the LFABM, upon encoun-
tering a dead agent, Kupffer cells phagocytize and become acti-
vated to produce TNF-α (a canonical pro-inflammatory cytokine)
and TGF-β1 (a canonical anti-inflammatory cytokine) (Mar-
tinez et al., 2008). Biologically, inadequate clearance of dead
cells can lead to the release of damage-associated molecular pat-
tern (DAMP) molecules such as HMGB1 (Scaffidi et al., 2002;
Bell et al., 2006). DAMPs attract monocytes and neutrophils
to the liver. Correspondingly, in the LFABM, inadequate clear-
ance of dead agents leads to accumulation of HMGB1, with
subsequent recruitment and transformation of monocytes to
activated Kupffer cells. All parameters are set with probabilistic
ranges.
High mobility group box protein 1 and TNF-α are potent
stimulants of portal fibroblasts and HSCs, inducing their trans-
formation to myofibroblasts (Knittel et al., 1997; Kao et al., 2008).
TGF-β1 is known to induce myofibroblastic proliferation and
deposition of ECM components (primarily type 1 collagen) by
these cells (Maher and McGuire, 1990; Friedman, 2000). In the
LFABM, agents representing portal fibroblasts and HSCs are acti-
vated and transformed to myofibroblast agents when they detect
TNF-α. When they detect TGF-β1, myofibroblast agents prolifer-
ate and deposit collagen to existing ECM structure (Thannickal
et al., 2003).
FIGURE 1 |The structural elements comprising the tissue framework.
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FIGURE 2 | An overview of agent interactions in the model. H,
hepatocyte; D, dead hepatocyte; KC, Kupffer cell; HSC, hepatic stellate cell;
PF, portal fibroblast; MF, myofibroblast. Diffusible factors TNF-α, tumor
necrosis factor alpha; TGF-β1, transforming growth factor beta 1; HMGB1,
high mobility group box protein 1. Detailed rules are available in
Supplementary Material.
MODEL CALIBRATION AND PARAMETER ESTIMATION
Hepatocytes account for approximately 60% of the total number
of cells found in the liver, whereas Kupffer cells account for 15%
and HSCs account for 5% (Malarkey et al., 2005). The initial num-
ber of hepatocytes in the LFABM was set by an automated process
of filling hepatocytes per lobule in a spiral fashion, beginning at the
center, and then allowing their collision and replication properties
to fill up the lobule uniformly. For the simulation size presented
in this paper, this number emerged to be 3,857. Considering this
to represent 60% of the cell population of the liver, the number of
Kupffer cells was initialized to 964, and the number of HSC to 321.
The agents were chosen to represent broad biological functions:
the Kupffer cell was a representative inflammatory cell, TNF-α
was a representative pro-inflammatory cytokine, and TGF-β1 was
a representative anti-inflammatory/pro-fibrotic cytokine. Agent
rules follow biological function, but not every intermediate is
modeled. For example, exposure to above-threshold levels of TNF-
α causes hepatocyte death in the LFABM. This bystander effect is
biologically mediated by T-cell activation, which is downstream
of Kupffer cell activation; however, we do not explicitly model
T-cells, instead treating the effect of TNF-α on hepatocytes as a
“lumped parameter” (Bhattacharya-Ghosh et al., 2012). Parame-
ters for lifespans and proliferation rates were calibrated such that,
in the absence of external perturbation, baseline equilibrium was
maintained for each agent type in the system. All of the parameter
values can be found in Supplementary Material.
SIMULATED ELASTOGRAPHY MEASUREMENT
A number of non-invasive techniques for evaluating liver fibro-
sis are currently in development. Some of these approaches
use ultrasound or magnetic resonance elastography to quantify
changes in the stiffness of liver tissue as a measure of fibrosis pro-
gression (Castera et al., 2005; Huwart et al., 2006; Takeda et al.,
2006; Yin et al., 2007). In our simulations, a measure of tissue
elasticity was obtained by calculating the average displacement of
all internal nodes (each node that has three adjoining septa) one
time step after a centrally (inward) directed impulse was applied
to every internal node, with all outer nodes (nodes that are on
the outer border of our simulated tissue patch) held immobile.
A higher displacement value would indicate a more pliable con-
dition of the tissue. Since this measurement requires an external
perturbation that could affect later states of the simulation, a copy
of the current state of the simulation was first saved, and then
the impulse applied to this copy. In this case, “state” refers to the
current positions of all agents, which contribute to tissue mechan-
ics, as well as their relevant physical forces. In order to make up
for the lack of compressibility – a natural biological quality of
hepatocytes in vivo – of the cellular agents, a slight reduction in
the diameter of each hepatocyte and dead agent was applied uni-
formly before applying the impulse. This allowed compression of
the tissue even when fully packed with hepatocytes or dead agents.
After the impulse was applied, and elastic displacement measured,
this copy of the state was discarded.
STATISTICAL ANALYSIS
All simulation plots are presented as mean± SD, using
SigmaPlot 9.0 from Systat Software, Inc., San Jose, CA, USA
(www.sigmaplot.com).
RESULTS
Of the various experimental models utilized in the study of liver
fibrosis and cirrhosis, carbon tetrachloride (CCl4)-induced cir-
rhosis in rodent livers is considered to be closest to human cirrhosis
in terms of morphology and pathophysiology (Perez Tamayo,
1983; Wu and Norton, 1996; Onori et al., 2000). Intoxication with
CCl4 results in hepatocyte damage, necrosis, inflammation, and
fibrosis, which spreads to link the vascular structures that feed into
the hepatic sinusoids, leading to cirrhosis over 8–12 weeks (Con-
standinou et al., 2005). Accordingly, the in silico development of
chronic inflammation and fibrosis in a patch of liver was verified
against a histological time course obtained from the liver of rats
exposed to CCl4.
At baseline, both tissue sections stained with Masson’s
trichrome (Figure 3A, left) and the simulation (Figure 3A,
right) show a uniform texture across hepatocyte-filled lobules.
As hepatocytes died in response to repeated CCL4 administra-
tion, persistent damage led to continuous inflammatory activation
(Figure 3B), loss of hepatocytes, and the beginnings of colla-
gen deposition – first in the periportal region, then extending
across septa to form bridging fibrosis. With continued inflam-
mation, collagen deposits grew and the lobules appeared more
deformed, with some regenerative nodules forming as fibrous
bands beginning to separate out smaller sections of parenchyma
(Figures 3C,D).
To characterize the quantitative rather than qualitative behav-
ior of the ABM, the predicted dynamics of cell populations and
cytokine production were assessed. Resident Kupffer cells were
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FIGURE 3 | (A–D) Progression of fibrosis in experimentally obtained sections (left column) vs. in ABM simulation (right column); collagen appears blue in
Masson’s trichrome stain (left), collagen agents in the model are also blue (right).
activated by the CCL4-induced damage, and a concomitant rise
in activated Kupffer cells and concurrent recruitment of further
Kupffer cells were observed (Figure 4A). The activation of Kupffer
cells slows down as the simulation progresses, but then stabilizes
to a steady state after about 300 simulation time steps (Figure S1 in
Supplementary Material). The Kupffer cell population was initially
dominated by an M1 phenotype, characterized by release of TNF-
α (Figure 4B). As Kupffer cells phagocytized dead hepatocytes,
their phenotype shifted toward an M2 phenotype, characterized
by release of TGF-β1.
A well-known consequence of fibrosis is an overall loss of
the liver’s natural elasticity (Wang et al., 2009). To determine if
the ABM exhibits this global behavior, a simulated elastography
measurement was utilized. The observed change in elastic displace-
ment, when measured periodically during a simulation, is shown
in Figure 5. After an initial increase in tissue pliability, the liver
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FIGURE 4 | General trajectory of Kupffer cell activation and cytokine
production in simulations (n=10, mean±SD). (A) Resident Kupffer cells
are at first quiescent (blue), but as inflammation progresses they are activated
(red) and drive further recruitment of Kupffer cells; (B) the trajectory of TNF-α
(red) and TGF-β1 (blue) as inflammation progresses. Activated Kupffer cells are
at first dominated by an M1 phenotype, as demonstrated by the early peak of
TNF-α, followed by a later, longer peak of TGF-β1 (transition to a domination of
M2 phenotype).
FIGURE 5 | Change in tissue elasticity with the progression of
fibrosis. (A) Snapshots of the model at intervals of 20 simulation
time steps. (B) Elastic displacement measured at each of the same
time points of simulations (n=10, mean±SD), as described in
Section “Materials and Methods.” Units are relative to set
simulation space.
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FIGURE 6 | Effect of anti-TNF treatment or M2 enhancement of
Kupffer cells in the simulations (n=10, mean±SD). (A) TGF-β1
levels in the model with anti-TNF treatment (red), and in the model
with enhanced M2 behavior (blue), compared to TGF-β1 levels in the
baseline model (black); (B) TNF-α levels in the model with anti-TNF
treatment (red), and in the model with enhanced M2 behavior (blue),
compared to TNF-α levels in the baseline model (black); (C) growth of
collagen in the anti-TNF-treated model (red), and in the model with
enhanced M2 behavior (blue), compared to growth of collagen in the
baseline model (black).
steadily becomes stiffer over time, as fibrotic bands begin to appear.
This behavior is consistent with clinical observations of fibrotic liv-
ers, where the mechanical properties of the liver tissue were found
to be correlated with the extent of fibrosis (Yin et al., 2007).
Next, the LFABM was used to test specific hypotheses regard-
ing two potential anti-fibrotic therapies: modulation of M1/M2
Kupffer cell phenotype, and the administration of neutralizing
anti-TNF-α antibodies. Although it is well-established that Kupf-
fer cells play a key role in the pathogenesis of liver fibrosis, their
participation has classically been associated with hepatic inflam-
mation and activation of HSCs (Bataller and Brenner, 2005). Prior
studies have explored the efficacy of anti-TNF-α treatments to
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reduce hepatic fibrosis, with some experimental evidence suggest-
ing that inhibition of TNF-α signaling during liver injury may
be efficacious (Bahcecioglu et al., 2008; Rockey, 2008). Kupffer
cells that have differentiated to an M2 phenotype, character-
ized by release of the anti-inflammatory cytokine TGF-β1, also
inhibit TNF-α signaling. However, experimental evidence has
shown that M2 Kupffer cells can promote fibrogenesis (Lopez-
Navarrete et al., 2011). To test the effect of these two mecha-
nisms of anti-inflammatory treatment on the growth of fibrosis,
the growth of collagen in the LFABM was examined under two
new conditions: first, in response to the presence of an anti-
TNF-α treatment (simulated by increasing the degradation rate
of local TNF-α); second, in response to increased production of
TGF-β1 by the Kupffer cell agents (thereby simulating enhanced
M2 activation). TGF-β1 levels were reduced in anti-TNF-α sim-
ulations (Figure 6A, red), and elevated in the simulations of
enhanced M2 behavior (Figure 6A, blue). TNF-α levels were
reduced in both the anti-TNF simulations (Figure 6B, red) and
the simulations of enhanced M2 behavior (Figure 6B, blue). The
amount of collagen in the anti-TNF simulations (Figure 6C,
red) was lower than untreated baseline, while the simulations
of enhanced M2 behavior showed substantially greater accu-
mulation of collagen (Figure 6C, blue) compared to untreated
baseline.
DISCUSSION
This manuscript describes a multiscale ABM developed in order to
simulate the development of chronic liver inflammation and fibro-
sis. This LFABM simulates key cellular and molecular processes of
inflammation and fibrosis, as well as behavior (overall elasticity) at
a tissue scale, ultimately generating predictions regarding dynam-
ics of cell populations, patterns of tissue fibrosis, and lobular struc-
ture, as well as overall mechanical and structural changes (Meier-
Schellersheim et al., 2009). The LFABM was verified through a
qualitative pattern-oriented analysis, wherein emergent patterns
are seen as defining characteristics of a system, and the ability of
an ABM to recreate these patterns is indicative of its value in gen-
erating and testing hypotheses regarding system-level properties
(Grimm et al., 2005). The development of fibrosis first periportally,
then bridging across septa, and then eventually leading to regen-
erative nodules and lobular deformation was observed both in the
LFABM and in a histological time course obtained from CCL4-
treated cirrhotic rats. This pattern of collagen deposition emerged
concurrent to the known biological time course of inflammation,
consisting of an early pro-inflammatory peak, followed by a slower,
late rise in anti-inflammatory/pro-fibrotic mediators. As fibrosis
progressed, the simulated tissue overall became less pliable, anal-
ogous to the increase in tissue stiffness seen clinically as well as
experimentally in CCl4-treated rats (Yin et al., 2007; Wang et al.,
2009).
The primary motivation in building this LFABM was to lever-
age the power of simulation experiments on a biologically realistic
system to examine the effects of potential anti-fibrotic strategies.
Thus, the model was used to test hypotheses in silico regarding the
role of Kupffer cells and TNF-α in the progression of fibrosis in the
liver. There is controversy over whether Kupffer cells are primarily
involved in cirrhosis as promoters of inflammation or fibrogene-
sis. An experimental approach to address this question selectively
stimulated alternate activation in mouse Kupffer cells, and found
that collagen levels were higher in these mice when treated with
CCl4 despite markedly lower levels of inflammatory cell popula-
tions in these animals (Lopez-Navarrete et al., 2011). Others have
observed that anti-inflammatory treatment could attenuate necro-
inflammation, and thereby fibrosis, in the CCl4-treated liver. One
such study involved the use of infliximab, an anti-TNF-α agent,
and reported lower fibrosis scores due to this treatment (Bahce-
cioglu et al., 2008). Our results are consistent with these latter
observations. In the study using infliximab, the authors reported
no significant difference in serum TNF-α levels, while observ-
ing relatively reduced levels of TGF-β1. It is possible, therefore,
that experimental suppression of TNF-α affects fibrosis through
mediation of TGF-β1 levels; similar effects were suggested in an
earlier ABM of inflammation in the setting of chronic, non-healing
diabetic foot ulcers (Mi et al., 2007).
A limitation of the multiscale modeling approach described
herein involves the abstraction across different scales of biological
organization. This abstraction includes choosing representative
cells and cytokines to represent overall mechanism, and using
“lumped parameters” to summarize the main effects of biologi-
cal processes (Bhattacharya-Ghosh et al., 2012). This abstraction
means that, inevitably, some mechanistic details of the system
being modeled are sacrificed. However, such simplification allows
us to define the main functional modules that lead to multiscale
emergent behaviors at the tissue level, and the liver as a whole. In a
similar vein,prior ABMs of diabetic foot ulcers (Mi et al., 2007) and
particulate-injured lung (Brown et al., 2011) abstracted inflamma-
tory cells as well as pro- and anti-inflammatory cytokines in a man-
ner similar to that depicted herein. In addition, the LFABM was not
calibrated against any specific time course of liver injury, though
simulations did match the general progression of CCl4-induced
histological changes. Future versions of this model could calibrate
the time course of simulated inflammation to clinically observed
time courses, with the goal of suggesting therapies for fibrosis in a
disease-specific, and perhaps also patient-specific manner.
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